Pentavalent vaccine: A major breakthrough in India's Universal Immunization Program

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 9, 2012, Pages 1314-1316

  Bairwa, Mohan ^a   Pilania, Manju ^a   Rajput, Meena ^a   Khanna, Pardeep ^a   Kumar, Neelam ^a   Nagar, Mukesh ^a   Chawla, Sumit ^a  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cost effectiveness; DPT; Haemophilus influenza type B; Hepatitis B; Immunization; Immunogenicity; Pentavalent vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE;

COST EFFECTIVENESS ANALYSIS; CRYING; DIPHTHERIA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; GOVERNMENT; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS MENINGITIS; HEALTH CARE COST; HEALTH PROGRAM; HEPATITIS; HEPATITIS B; HUMAN; IMMUNOGENICITY; INDIA; INFECTION CONTROL; INFECTION PREVENTION; IRRITABILITY; MASS IMMUNIZATION; NEWBORN TETANUS; NOTE; PERTUSSIS; SIDE EFFECT; TETANUS;

BACTERIAL CAPSULES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INDIA; VACCINES, COMBINED;

EID: 84866980720     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20651     Document Type: Note

References (32)

1. Ministry of health and family welfare. Immunization handbook for medical officers. New Delhi: Government of India, 2009.
2. Registrar General of India. Provisional Population Totals Paper 1 of 2011 India Series 1. New Delhi: Office of the Registrar General and Census Commissioner of India, 2011.
3. Registrar General of India. Sample registration system: measures of fertility and mortality in India. New Delhi: Government of India, 2011.
4. Sharma S. Immunization coverage in India. New Delhi: Institute of Economic Growth; 2007. Working paper series No. E/283/2007.
5. International Institute of Population Sciences. NFHS-1, 1992-93. Summary of findings. Mumbai;IIPS, 1995.
6. International Institute of Population Sciences. ORC Macro. NFHS-2, 1998-99. Summary of findings. Mumbai:IIPS, 2000.
7. International Institute for Population Sciences. Reproductive and Child Health. District Level Household Survey (DLHS-2) 2002-04 India. Mumbai:IIPS, 2006.
8. International Institute for Population Sciences. District Level Household and Facility Survey 200708. Mumbai:IIPS, 2010.
9. UNICEF. Coverage Evaluation Survey, 2009. All India Report. New Delhi: UNICEF, 2010. Available from: http://www.unicef.org/india/National-Fact-Sheet- CES-2009.pdf.
10. Shea B, Andersson N, Henry D. Increasing the demand for childhood vaccination in developing countries: a systematic review. BMC Int Health Hum Rights 2009; 9(Suppl 1):S5; PMID:19828063; http://dx.doi.org/10.1186/1472-698X- 9-S1-S5.
11. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999; 103:321-5; PMID:9949325; http://dx.doi.org/10.1016/S0091-6749(99)70508-7.
12. Halsey NA. Limiting infant exposure to thimerosal in vaccines and other sources of mercury. JAMA 1999; 282:1763-6; PMID:10568650; http://dx.doi.org/10. 1001/jama.282.18.1763.
13. Available from. http://www.gavialliance.org/support/nvs/hib/
14. Available from. http://www.unicef.org/supply/files/8.-DTP-containing- vaccines-including-pentavalent-and-hexavalent.pdf
15. Minz S, Balraj V, Lalitha MK, Murali N, Cherian T, Manoharan G, et al. Incidence of Haemophilus influenzae type b meningitis in India. Indian J Med Res 2008; 128:57-64; PMID:18820360.
16. Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria- Knoll M, McCall N, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374:903-11; PMID:19748399; http://dx.doi.org/10.1016/S0140-6736(09)61203-4.
17. Singhi P, Bansal A, Geeta P, Singhi S. Predictors of long term neurological outcome in bacterial meningitis. Indian J Pediatr 2007; 74:369-74; PMID:17476082; http://dx.doi.org/10.1007/s12098-007-0062-6.
18. Kabra SK, Kumar P, Verma IC, Mukherjee D, Chowdhary BH, Sengupta S, et al. Bacterial meningitis in India: an IJP survey. Indian J Pediatr 1991; 58:505-11; PMID:1800332; http://dx.doi.org/10.1007/BF02750932.
19. Chinchankar N, Mane M, Bhave S, Bapat S, Bavdekar A, Pandit A, et al. Diagnosis and outcome of acute bacterial meningitis in early childhood. Indian Pediatr 2002; 39:914-21; PMID:12428036.
20. Invasive Bacterial Infections Surveillance (IBIS) Group of the International Clinical Epidemiology Network. Are Haemophilus influenzae infections a significant problem in India? A prospective study and review. Clin Infect Dis 2002; 34:949-57; PMID:11880961; http://dx.doi.org/10.1086/339327.
21. Das BK, Arora NK, Mathur P, Ostwal P, Mandal S, Kabra SK, et al. Nasopharyngeal carriage of Haemophilus influenzae. Indian J Pediatr 2002; 69:775-7; PMID:12420910; http://dx.doi.org/10.1007/BF02723690.
22. Verma R, Khanna P, Prinja S, Rajput M, Chawla S, Bairwa M. Hepatitis B Vaccine in national immunization schedule: a preventive step in India. Hum Vaccin 2011; 7:1387-8; PMID:22134433; http://dx.doi.org/10.4161/hv.7.12.17878.
23. Sharma HJ, Yadav S, Lalwani SK, Kapre SV, Jadhav SS, Chakravarty A, et al. Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children. Hum Vaccin 2011; 7:451-7; PMID:21403463; http://dx.doi.org/10.4161/hv.7.4.14208.
24. Bavdekar SB, Maiya PP, Subba Rao SD, Datta SK, Bock HL. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants. Indian Pediatr 2007; 44:505-10; PMID:17684303.
25. Ali SS, Chandrashekar SR, Singh M, Bansal RK, Sharma DR, Arora D. A multicenter, prospective, open-label, non-comparative study to evaluate the immunogenicity and tolerance of a new, fully liquid pentavalent vaccine (DTwP-HepB-Hib vaccine). Hum Vaccin 2007; 3:116-20; PMID:17617743; http://dx.doi.org/10.4161/hv.3.4.4061.
26. Rao R, Dhingra MS, Bavdekar S, Behera N, Daga SR, Dutta AK, et al. A comparison of immunogenicity and safety of indigenously developed liquid (DTwPHB-Hib) pentavalent combination vaccine (Shan 5) with Easyfive (liq) and TritanrixHB + Hiberix (lyo) in Indian infants administered according to the EPI schedule. Hum Vaccin 2009; 5:425-9; PMID:19333002.
27. Chatterjee S, Rego SJ, D'Souza F, Bhatia BD, Collard A, Datta SK, et al. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule. BMC Infect Dis 2010; 10:298; PMID:20950457; http://dx.doi.org/10.1186/1471-2334-10-298.
28. Subcommittee on Introduction of Hib Vaccine in Universal Immunization Program, National Technical Advisory Group on Immunization, India. NTAGI subcommittee recommendations on Haemophilus influenzae type B (Hib) vaccine introduction in India. Indian Pediatr 2009; 46:945-54; PMID:19955578.
29. Nair H, Hazarika I, Patwari A. A roller-coaster ride: Introduction of pentavalent vaccine in India. J Glob Health 2009; 1:32-5.
30. Gupta M, Prinja S, Kumar R, Kaur M. Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India. Health Policy Plan. 2012 Mar 8. [Epub ahead of print]
31. Government of India. Meeting of the National Technical Advisory Group on Immunization 16 June, 2008 - Minutes and Recommendations. New Delhi: Government of India, 2008.
32. Press Information Bureau, Government of India. http://pib.nic.in/newsite/ erelease.aspx?relid=79191. English Release 17-April 2012.